{"product_id":"amgen-swot-analysis","title":"Amgen SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAmgen's innovative pipeline and strong market presence are significant strengths, but the company also faces challenges like patent expirations and increasing competition. Understanding these dynamics is crucial for any investor or strategist looking to capitalize on opportunities within the biotechnology sector.\u003c\/p\u003e\n\u003cp\u003eReady to dive deeper into Amgen's strategic landscape? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support your planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong and Diverse Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen's strength lies in its exceptionally strong and diverse product portfolio. In 2024, a significant 21 of its products achieved record sales, underscoring the broad market acceptance and commercial success of its offerings. This robust performance is driven by key growth drivers such as Repatha, TEZSPIRE, and EVENITY, which are making substantial contributions to the company's revenue streams.\u003c\/p\u003e\n\u003cp\u003eThis diversification is not just about quantity; it's strategically spread across critical therapeutic areas. Amgen has a strong presence in oncology, nephrology, inflammation, and cardiovascular diseases. This multi-faceted approach provides considerable resilience, allowing the company to weather market downturns or competitive pressures in any single area more effectively.\u003c\/p\u003e\n\u003cp\u003eFurthermore, Amgen's strategic focus on addressing high unmet medical needs is a crucial element of its strength. By developing innovative human therapeutics for conditions where treatment options are limited, the company ensures a sustained and consistent demand for its products, building a solid foundation for future growth and market leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Performance and Cash Flow Generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen showcased a robust financial performance in 2024, with total revenues climbing 19% to reach $33.4 billion. Product sales saw a significant jump of 23%, underscoring the strength of its core business.\u003c\/p\u003e\n\u003cp\u003eThe company's ability to generate substantial free cash flow, amounting to $10.4 billion in 2024, is a testament to its operational efficiency. This strong cash generation capability positions Amgen favorably for future investments, shareholder returns, and managing its debt obligations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R\u0026amp;D Capabilities and Promising Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen boasts formidable research and development strengths, evidenced by its extensive pipeline featuring over 35 investigational candidates. This robust pipeline includes significant assets such as MariTide, targeting obesity, and olpasiran, aimed at reducing cardiovascular risk. \u003c\/p\u003e\n\u003cp\u003eThe company's dedication to pioneering innovation, especially in genetic and protein engineering, is a key driver for future breakthroughs. This focus on cutting-edge science underpins Amgen's strategy for sustained growth and market leadership in the biopharmaceutical sector.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisitions and Biosimilar Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmgen's strategic acquisitions have significantly bolstered its market position. The $27.8 billion acquisition of Horizon Therapeutics in 2023 was a key move, enhancing its rare disease offerings with crucial products like TEPEZZA and KRYSTEXXA.\u003c\/p\u003e\n\u003cp\u003eThe company is also a recognized leader in the biosimilars sector. Amgen's biosimilar sales reached $2.2 billion in 2024, with projections indicating a near doubling to $4 billion by 2030.\u003c\/p\u003e\n\u003cp\u003eAmgen's approach to being an early entrant in the biosimilar market, launching products like Pavblu and Wezlana, provides a distinct competitive edge.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Acquisitions:\u003c\/strong\u003e The $27.8 billion acquisition of Horizon Therapeutics in 2023 significantly strengthened Amgen's rare disease portfolio.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiosimilar Leadership:\u003c\/strong\u003e Biosimilar sales reached $2.2 billion in 2024 and are projected to nearly double to $4 billion by 2030.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Amgen's strategy of being a 'first wave' biosimilar launcher, including products like Pavblu and Wezlana, offers a distinct market advantage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Presence and Established Brand Reputation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmgen boasts a robust global footprint, actively engaging in over 50 countries and employing approximately 28,000 individuals as of early 2024. This extensive international presence, coupled with a strong brand reputation built on a commitment to enhancing patient lives, solidifies its position as a leader in the biotechnology sector.  Its established network and trusted name are instrumental in achieving wider market penetration and ensuring patient access to its innovative therapies.\u003c\/p\u003e\n\u003cp\u003eThe company's brand recognition is a significant asset, enabling it to connect with healthcare providers and patients across diverse markets. This global reach, supported by a dedicated workforce, allows Amgen to effectively distribute its products and gather valuable market insights, fostering continuous growth and development.\u003c\/p\u003e\n\u003cp\u003eKey aspects of Amgen's global strength include:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eExtensive Operational Reach:\u003c\/strong\u003e Operations in over 50 countries worldwide.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSignificant Workforce:\u003c\/strong\u003e Approximately 28,000 employees contributing to its global efforts.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrong Brand Equity:\u003c\/strong\u003e A well-recognized and trusted brand in the biopharmaceutical industry.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Leadership:\u003c\/strong\u003e Demonstrated ability to penetrate and lead in key therapeutic areas globally.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePioneering Biopharma: Innovation, Growth, and Global Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen's diversified product portfolio is a significant strength, with 21 products achieving record sales in 2024, driven by strong performers like Repatha and TEZSPIRE. This broad market acceptance across oncology, nephrology, inflammation, and cardiovascular diseases provides crucial resilience against market fluctuations.\u003c\/p\u003e\n\u003cp\u003eThe company's financial health is robust, evidenced by a 19% revenue increase to $33.4 billion in 2024 and $10.4 billion in free cash flow, enabling strategic investments and shareholder returns.\u003c\/p\u003e\n\u003cp\u003eAmgen's commitment to innovation is highlighted by an extensive pipeline of over 35 investigational candidates, including promising treatments for obesity and cardiovascular risk, supported by pioneering work in genetic and protein engineering.\u003c\/p\u003e\n\u003cp\u003eStrategic acquisitions, such as the $27.8 billion purchase of Horizon Therapeutics in 2023, have significantly enhanced its rare disease offerings with key products like TEPEZZA.\u003c\/p\u003e\n\u003cp\u003eAmgen is a leader in the biosimilars market, with sales reaching $2.2 billion in 2024 and projected to hit $4 billion by 2030, bolstered by early market entry with products like Pavblu and Wezlana.\u003c\/p\u003e\n\u003cp\u003eIts global presence, spanning over 50 countries with approximately 28,000 employees, and a strong, trusted brand reputation, facilitates market penetration and patient access to its therapies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003cth\u003eKey Drivers\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenues\u003c\/td\u003e\n\u003ctd\u003e$33.4 billion (+19%)\u003c\/td\u003e\n\u003ctd\u003eStrong product sales growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Sales\u003c\/td\u003e\n\u003ctd\u003eSignificant 23% jump\u003c\/td\u003e\n\u003ctd\u003eRepatha, TEZSPIRE, EVENITY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow\u003c\/td\u003e\n\u003ctd\u003e$10.4 billion\u003c\/td\u003e\n\u003ctd\u003eOperational efficiency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar Sales\u003c\/td\u003e\n\u003ctd\u003e$2.2 billion\u003c\/td\u003e\n\u003ctd\u003eEarly market entry, Pavblu, Wezlana\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Pipeline\u003c\/td\u003e\n\u003ctd\u003e35+ investigational candidates\u003c\/td\u003e\n\u003ctd\u003eMariTide (obesity), olpasiran (cardiovascular)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Operations\u003c\/td\u003e\n\u003ctd\u003e50+ countries\u003c\/td\u003e\n\u003ctd\u003e~28,000 employees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Amgen’s internal and external business factors, identifying key strengths, weaknesses, opportunities, and threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a clear, actionable framework to address Amgen's competitive challenges and capitalize on its strengths.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Dependency on Key Products and Impending Patent Expirations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen's reliance on a few key drugs presents a significant vulnerability. The company faces substantial revenue challenges as patents for blockbuster treatments like Prolia and Xgeva are set to expire in 2025. These medications were major revenue drivers, and their loss of exclusivity could create a considerable financial gap.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncreased Debt from Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen's significant $27.8 billion acquisition of Horizon Therapeutics in 2023, while strategically sound for portfolio expansion, has undeniably increased its debt load. This move, though aimed at long-term growth, presents a near-term challenge by reducing financial flexibility.\u003c\/p\u003e\n\u003cp\u003eThe substantial debt incurred from this acquisition could potentially strain Amgen's balance sheet strength. This increased leverage may also negatively impact key financial metrics such as return on invested capital, as the company works to integrate the new assets and manage its expanded financial obligations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing Pressures and Competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen faces significant pricing pressures from governments and healthcare payers worldwide, as they strive to manage rising healthcare expenditures. This ongoing challenge directly impacts the company's ability to maintain premium pricing for its innovative therapies.\u003c\/p\u003e\n\u003cp\u003eThe competitive landscape is intensifying with the increasing presence of biosimilar alternatives for Amgen's established blockbuster drugs. For instance, the loss of exclusivity for Enbrel and Otezla has already led to market share erosion and downward pressure on pricing, directly affecting revenue streams for these key products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline Setbacks and R\u0026amp;D Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmgen has encountered challenges with its drug development pipeline, notably an FDA clinical hold on its early-stage obesity drug candidate, AMG 513. The company has also discontinued other research programs, indicating potential hurdles in bringing new therapies to market.\u003c\/p\u003e\n\u003cp\u003eThese setbacks, coupled with rising research and development (R\u0026amp;D) expenditures, present a significant concern. For instance, Amgen's R\u0026amp;D expenses increased by 10% to $3.9 billion in 2023, and further increases are projected for 2024 as they advance their pipeline. This escalating cost, combined with the possibility of further development delays, could negatively affect Amgen's future financial performance and earnings outlook.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA clinical hold on obesity asset AMG 513.\u003c\/li\u003e\n\u003cli\u003eDiscontinuation of other promising research programs.\u003c\/li\u003e\n\u003cli\u003eProjected increases in R\u0026amp;D spending beyond the $3.9 billion in 2023.\u003c\/li\u003e\n\u003cli\u003ePotential impact on earnings due to development delays and high R\u0026amp;D costs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Litigation Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmgen faces considerable headwinds from ongoing regulatory scrutiny and significant litigation. A notable example is the pending tax litigation, which carries the potential for substantial financial penalties, impacting its bottom line. \u003c\/p\u003e\n\u003cp\u003eFurthermore, the company is entangled in legal challenges that directly threaten its market standing. The antitrust lawsuit initiated by Sandoz concerning Enbrel highlights these risks, potentially affecting Amgen's revenue streams and competitive advantage in key therapeutic areas.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Hurdles:\u003c\/strong\u003e Amgen operates in a highly regulated industry, with ongoing compliance requirements and potential for new regulations impacting product development and sales.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTax Litigation:\u003c\/strong\u003e The company is involved in tax disputes that could lead to significant financial liabilities, as seen in past cases involving large pharmaceutical companies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntitrust Lawsuits:\u003c\/strong\u003e Legal challenges, such as the Sandoz lawsuit over Enbrel, can result in market access restrictions or financial penalties, directly impacting Amgen's market share and profitability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTriple Threat: Patent Cliffs, R\u0026amp;D Setbacks, Legal Battles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen's reliance on a few key drugs presents a significant vulnerability, especially with patent expirations looming. For instance, Prolia and Xgeva, major revenue generators, face patent cliffs in 2025, potentially creating substantial financial gaps. This dependence on a limited product portfolio exposes Amgen to significant revenue volatility as exclusivity periods end.\u003c\/p\u003e\n\u003cp\u003eThe company's robust R\u0026amp;D spending, which increased by 10% to $3.9 billion in 2023 and is projected to rise further in 2024, also poses a weakness. Despite these investments, Amgen has faced setbacks, including an FDA clinical hold on its obesity drug candidate AMG 513 and the discontinuation of other research programs, highlighting potential challenges in bringing new therapies to market and impacting future earnings.\u003c\/p\u003e\n\u003cp\u003eAmgen is also susceptible to intense pricing pressures from global healthcare payers and faces significant litigation risks. The pending tax litigation could result in substantial financial penalties, while antitrust lawsuits, like the one from Sandoz concerning Enbrel, threaten market share and profitability.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eAmgen SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview reflects the real document you'll receive—professional, structured, and ready to use. It offers a clear overview of Amgen's strategic positioning. Purchase unlocks the complete, in-depth analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610603176313,"sku":"amgen-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/amgen-swot-analysis.png?v=1754741037","url":"https:\/\/growthsharematrix.com\/products\/amgen-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}